Macquarie Group
TVTX icon

Macquarie Group’s Travere Therapeutics TVTX Stock Holding History

Macquarie Group’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4,984,333
Closed -$119M – 1464
2025
Q3 		$119M Sell
4,984,333
-113,149
-2% -$2.13M 0.14% 175
2025
Q2 		$75.4M Buy
5,097,482
+300,168
+6% +$4.98M 0.09% 303
2025
Q1 		$86M Buy
4,797,314
+537,757
+13% +$10.9M 0.11% 268
2024
Q4 		$74.2M Sell
4,259,557
-13,357
-0.3% -$236K 0.09% 311
2024
Q3 		$59.8M Sell
4,272,914
-94,916
-2% -$989K 0.06% 398
2024
Q2 		$35.9M Sell
4,367,830
-245,229
-5% -$1.65M 0.04% 506
2024
Q1 		$35.6M Sell
4,613,059
-133,717
-3% -$1.13M 0.04% 532
2023
Q4 		$42.7M Buy
4,746,776
+74,917
+2% +$545K 0.05% 479
2023
Q3 		$41.8M Buy
4,671,859
+718,745
+18% +$10.1M 0.05% 456
2023
Q2 		$60.7M Buy
3,953,114
+308,427
+8% +$5.61M 0.07% 363
2023
Q1 		$82M Buy
3,644,687
+88,575
+2% +$1.88M 0.1% 279
2022
Q4 		$74.8M Buy
3,556,112
+245,856
+7% +$5.21M 0.09% 317
2022
Q3 		$81.6M Sell
3,310,256
-358,423
-10% -$9.26M 0.1% 279
2022
Q2 		$88.9M Buy
3,668,679
+55,778
+2% +$1.4M 0.1% 269
2022
Q1 		$93.1K Sell
3,612,901
-154,991
-4% -$4.12M 0.07% 313
2021
Q4 		$117M Sell
3,767,892
-183,949
-5% -$5.18M 0.1% 275
2021
Q3 		$95.8M Buy
3,951,841
+39,428
+1% +$724K 0.08% 312
2021
Q2 		$57.1M Buy
3,912,413
+1,174,860
+43% +$23.2M 0.05% 496
2021
Q1 		$68.4M Sell
2,737,553
-26,369
-1% -$729K 0.1% 260
2020
Q4 		$75.3M Sell
2,763,922
-441,682
-14% -$10.3M 0.11% 207
2020
Q3 		$59.2M Sell
3,205,604
-303,324
-9% -$5.9M 0.1% 215
2020
Q2 		$71.6M Buy
3,508,928
+150,927
+4% +$2.4M 0.12% 177
2020
Q1 		$49M Buy
3,358,001
+280,812
+9% +$4.22M 0.1% 214
2019
Q4 		$43.7M Buy
3,077,189
+388,488
+14% +$4.96M 0.06% 330
2019
Q3 		$31.2M Buy
2,688,701
+91,777
+4% +$1.52M 0.05% 360
2019
Q2 		$52.2M Buy
2,596,924
+97,848
+4% +$1.93M 0.09% 254
2019
Q1 		$56.6M Buy
2,499,076
+233,152
+10% +$5.15M 0.1% 218
2018
Q4 		$51.3M Buy
2,265,924
+339,588
+18% +$8.45M 0.1% 209
2018
Q3 		$55.3M Buy
1,926,336
+308,718
+19% +$8.83M 0.09% 236
2018
Q2 		$44.1M Buy
1,617,618
+177,604
+12% +$4.73M 0.08% 276
2018
Q1 		$32.2M Buy
1,440,014
+99,365
+7% +$2.37M 0.06% 349
2017
Q4 		$28.2M Sell
1,340,649
-118,569
-8% -$2.71M 0.05% 389
2017
Q3 		$36.3M Buy
1,459,218
+270,399
+23% +$5.95M 0.07% 299
2017
Q2 		$23.1M Buy
1,188,819
+172,389
+17% +$3.13M 0.04% 415
2017
Q1 		$18.8M Buy
1,016,430
+137,149
+16% +$2.68M 0.03% 472
2016
Q4 		$16.6M Buy
879,281
+61,549
+8% +$1.26M 0.03% 491
2016
Q3 		$18.3M Sell
817,732
-1,040,900
-56% -$19.8M 0.04% 441
2016
Q2 		$33.1M Buy
1,858,632
+1,337,597
+257% +$21.7M 0.03% 430
2016
Q1 		$7.12M Buy
521,035
+66,832
+15% +$1.01M 0.01% 629
2015
Q4 		$8.76M Buy
454,203
+158,360
+54% +$3.16M 0.02% 576
2015
Q3 		$5.99M Buy
295,843
+85,040
+40% +$2.52M 0.01% 671
2015
Q2 		$6.99M Buy
+210,803
New +$5.77M 0.01% 655

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Macquarie Group's TVTX Position: Q4 2025 in Review

Macquarie Group sold out of Travere Therapeutics (TVTX) in Q4 2025, closing a stake of 4,984,333 shares — an estimated $119M sold.

Macquarie Group first reported a position in TVTX in Q2 2015 and held it in 42 quarters. The position peaked at $119M in Q3 2025. 278 funds tracked by Wall St. Rank hold TVTX as of Q4 2025.

  • Macquarie Group reported no remaining Travere Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Macquarie Group sold 4,984,333 Travere Therapeutics shares in Q4 2025, an estimated $119M.
  • Macquarie Group first reported a position in Travere Therapeutics in Q2 2015 and held it in 42 quarters.
  • Macquarie Group's Travere Therapeutics position peaked at $119M in Q3 2025.
  • 278 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2025.

Based on Macquarie Group's 13F filing for Q4 2025, filed 13 Feb 2026.